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Introduction
The incidence of obesity and, consequently, obesity-related 
co-morbidities is rapidly increasing in both the developed 
and developing worlds. Recently, the importance of total 
body adiposity has been eclipsed by the finding that 
visceral fat associated with central obesity contributes more 
to pathogenicity than subcutaneous fat.1 This may be due to 
the greater ability of visceral than subcutaneous adiposity 
to increase insulin resistance1 which, in turn, is thought to 
be an important aetiological factor in the development of 
type 2 diabetes, dyslipidaemia and cardiovascular disease.2 
Body fat distribution is therefore highly important and may 
be seen as a possible future predictor of obesity-related 
disease. Understanding the factors that regulate body fat 
distribution should not only give insight into the aetiology 
of obesity-related co-morbidities but also potentially allow 
for different therapeutic interventions depending on body 
phenotype. Whereas increased lipid accumulation in the 
visceral adipose depot may contribute more to whole- 
body insulin resistance than a comparable expansion in 
subcutaneous fat,1 it is possible that insulin resistance may 
regulate lipid accumulation differentially in subcutaneous 
and visceral adipose depots. This review will discuss 
how insulin resistance, gender, hereditary factors and 
glucocorticoids may sculpture body fat and change the 
pathogenicity of obesity.
Insulin resistance and body fat 
distribution
The physiological purpose of insulin resistance may be 
to limit triglyceride deposition within adipocytes and thus 
reduce the accumulation of additional body fat mass in 
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obese subjects.3 This is likely to be a remnant of an archaic 
response that would have limited weight gain in our distant 
ancestors, maintaining mobility and allowing them to avoid 
predation. Accordingly, it has been found that subjects with 
the highest level of insulin resistance gain less weight over 
time.4,5 Thus, a study of 192 Pima Indians demonstrated 
that those with insulin resistance gained less weight than 
insulin-sensitive subjects (3.1 versus 7.6 kg; p<0.0001) 
over a period of 3.5 years.4 In addition, an investigation 
examining 95 children with an age range of 9.7–14.5 years 
showed that, after three years of follow-up, weight gain was 
lowest in those in the highest tertile of insulin resistance for 
both boys and girls.5
The accumulation of triglyceride in the subcutaneous 
and visceral adipose tissue depots does not occur at the 
same rate. The greater insulin sensitivity of subcutaneous 
compared to visceral adipose tissue6,7 allows the former 
depot to expand at a quicker rate in response to lipid 
loading in non-obese subjects. With increasing body mass 
index (BMI), the subcutaneous depot will expand and insulin 
resistance will increase, and this will lead to a reduction in 
the rate of both adipocyte hyperplasia and hypertrophy at 
this site. Triglycerides not taken up by the subcutaneous 
adipose tissue will then accumulate in the visceral depot, 
a process driven by hyperinsulinaemia. Triglycerides will 
also be deposited at ectopic sites such as the liver, skeletal 
muscle and islet β-cells.8 This process of lipid ‘overflow’ from 
the subcutaneous to the visceral depot has been postulated 
by a number of investigators,9,10 and a recent publication has 
suggested that the factor that limits triglyceride deposition 
within the subcutaneous depot is insulin resistance.11 The 
net result of increased visceral adiposity and ectopic fat 
deposition will be much higher levels of insulin resistance, 
but with a small change in total body fat. This may have 
been an important evolutionary adaption that occurred 
in our ancestors to limit fat deposition during periods of 
higher nutrient intake. However, in modern times cheap, 
calorie-dense foods are plentiful in all developed and 
most developing countries, and this metabolic process 
for limiting weight gain may now have been overwhelmed 
by excessive caloric intake. The consequence of this is a 
high population level of visceral adiposity, leading to an 
increased prevalence of the metabolic disorders associated 
with obesity.8,12,13
The lower level of insulin resistance in subcutaneous, 
compared to visceral, adipocytes would mean that, in 
subjects with a low/normal BMI, fat deposition will occur 
primarily in the subcutaneous depot whilst, in subjects 
with a higher BMI, subcutaneous lipid accumulation will be 
slower but triglyceride deposition in the visceral depot will 
be enhanced. This sequential expansion of adipose depots 
in response to rising levels of insulin resistance has been 
observed in epidemiological studies,14,15 in which a rapid 
increase in waist circumference occurs only at high levels 
of insulin resistance. Also, a study has shown that, in lean 
subjects, free fatty acid uptake in subcutaneous adipose 
tissue is much higher than that observed in obese, insulin-
resistant subjects.16
Insulin resistance is not the only agent that controls body 
fat distribution, with gender, genes and glucocorticoids 
all having important roles. However, it is possible that the 
influence of these factors on body fat depot size occurs via 
the modulation of insulin sensitivity.
Gender-related differences in body fat 
distribution    
Gender differences are observed in body fat distribution, 
with women tending to have less visceral but more 
subcutaneous fat than men.17,18 These differences are 
thought to be due to the effects of the sex steroids,19 
although the mechanisms by which they influence body 
fat distribution are not fully understood. Given the possible 
role of insulin sensitivity in modifying adipose tissue depot 
size, it is tempting to speculate that the sex steroids may 
influence the responsiveness of adipocytes to insulin, and 
there is some evidence to support this.
Oestrogen may increase subcutaneous fat deposition in 
women by increasing insulin sensitivity. Studies in the ob/
ob mouse have shown that administration of oestrogen 
leads to improved insulin sensitivity,20 and adipocytes 
isolated from rats treated with oestrogen have higher 
insulin receptor numbers21 and increased insulin binding.22 
Oestrogen may also have effects downstream of the insulin 
receptor, as treatment of the murine 3T3-L1 adipocyte 
cell line was found to increase insulin-stimulated glucose 
uptake, mediated by increased tyrosine phosphorylation 
of insulin receptor substrate 1.23 Furthermore, the effect of 
oestrogen on insulin signalling has been recapitulated in 
humans, with naturally occurring mutations of oestrogen 
receptor-α resulting in insulin resistance.24
Testosterone in men is associated with lower levels of 
both visceral25 and subcutaneous26 adiposity and reduced 
triglyceride uptake into subcutaneous adipocytes.27 These 
effects may be mediated by the ability of testosterone to 
reduce insulin sensitivity by affecting signalling downstream 
of the insulin receptor. An in vitro study of human 
subcutaneous adipocytes showed that administration of 
testosterone led to reduced insulin-stimulated glucose 
uptake, which was mediated by a reduced level of protein 
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kinase C ζ phosphorylation.28 Testosterone may also 
indirectly reduce insulin sensitivity, since it has been shown 
that testosterone treatment of men leads to lower serum 
levels of adiponectin.29
The ability of sex steroids to modulate body fat distribution 
may not only be due to their effects on insulin sensitivity. 
A number of in vitro experiments and animal studies have 
shown that both testosterone and oestrogen can directly 
alter adipocyte metabolism via interactions with androgen 
and oestrogen receptors.30 Furthermore, it is also known 
that adipocytes express enzymes that metabolise sex 
steroids. Thus, aldo-ketoreductase 1C enzymes (AKR1C) 
metabolise androgens, whilst aromatase converts 
androgens to oestrogens. The former enzymes may be 
important in regulating body fat distribution, as studies have 
shown that increased visceral adiposity is related to higher 
levels of AKR1C expression.31,32 It is therefore possible that 
android and gynoid body fat distribution are partly the result 
of the level of secreted sex hormones, as well as adipose 
depot-specific differences in the level of expression of the 
enzymes that metabolise testosterone and oestrogen and 
of the respective sex hormone receptors.
Data therefore demonstrate that oestrogen has insulin-
sensitising20,23 and testosterone has insulin-desensitising 
effects on adipocytes,28 which may lead to increased lipid 
storage in women compared to men. The direct effects of 
the sex steroids on adipocyte metabolism30 would augment 
these gender differences. Therefore, with increasing BMI, 
women would accumulate more fat in the subcutaneous 
depot than men, whilst men would begin to accumulate fat 
in the visceral depot at a lower BMI than do women. Such 
patterns have been observed in cross-sectional studies.17,33 
However, longitudinal investigations of body fat deposition 
across genders, as well as studies to analyse the effects of 
the sex steroids on insulin sensitivity in both subcutaneous 
and visceral adipocytes, are required to confirm these data. 
Genetic input into body fat distribution
Adipose tissue depot size has important consequences, 
both metabolically and physically, and therefore the 
mechanisms that modulate body fat distribution must 
have a number of control points that allow efficient and 
appropriate regulation. The most basic of these regulatory 
inputs is from the genome. Evidence for a strong genetic 
input into body fat distribution comes from heritability 
studies that show that 50–55% of the variance in visceral 
fat mass is derived from genetic factors.34 Nevertheless, a 
recent investigation has shown that gene polymorphisms 
that affect appetite regulation and that have been repeatedly 
linked to BMI in genome-wide association (GWA) studies 
do not associate with MRI-assessed levels of visceral and 
subcutaneous fat.35 These findings were confirmed in two 
GWA studies in which visceral and subcutaneous adipose 
tissue depot size36 and waist-to-hip ratio37 were linked with 
novel gene polymorphisms that had not previously been 
uncovered in GWA studies that used BMI as the principal 
phenotype. These polymorphisms were near genes 
that may be functionally linked to body fat distribution, 
namely regulator of G-protein signalling 6 (RSG6)36 and 
lysophospholipase-like protein 1 (LYPLAL1).37 The gene 
RSG6 encodes a protein that has been linked to opioid-
associated signalling,38 which would in turn modulate 
cortisol secretion. LYPLAL1 is a triglyceride lipase that is 
involved in the control of triglyceride breakdown within 
adipocytes.37 A third gene, insulin-induced gene 2 (INSIG2), 
has also been linked to visceral and subcutaneous adipose 
depot mass39 and to BMI in some, but not all, association 
studies.40,41 These inconsistent results have been attributed 
to INSIG2 being more strongly associated with body fat 
distribution than with total adiposity.39 INSIG2 has been 
proposed to function in the feedback inhibition of fatty acid 
and cholesterol synthesis.42
Polymorphisms in the fat mass and obesity-associated 
(FTO) gene show the strongest and most frequently 
replicated associations with obesity.43 However, only one 
study has looked at the input of genetic variation at this 
site on visceral and subcutaneous adipose depot size.44 
This investigation reported that a single polymorphism in 
the FTO gene was related to BMI, body weight and total 
body fat mass, as well as both visceral and subcutaneous 
adiposity. This demonstrates that sequence variation in the 
FTO gene modulates body fat depot size, but this is largely 
due to its effect on total body fat mass.
These data demonstrate that the genetic aetiology of 
total body adiposity may be different from that of body 
fat distribution. It is also possible that eligible candidate 
genes for regulating body fat distribution may control 
adipose tissue insulin sensitivity, and it is noteworthy that 
polymorphisms close to the insulin receptor substrate (IRS) 
1 gene have been associated with increased visceral fat levels 
in a genome-wide linkage scan.45 However, this result needs 
to be replicated in a larger patient cohort. The association 
of INSIG1 polymorphisms with body fat distribution also 
implicates adipocyte insulin responsiveness as a possible 
factor in the control of visceral and subcutaneous adipose 
depot mass.
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The role of glucocorticoids in the control 
of body fat distribution
Body fat distribution is influenced by hormones other than 
insulin, particularly the glucocorticoids, which directly modify 
adipocyte gene transcription and promote adipocyte insulin 
resistance.46,47 Thus, increased visceral fat mass observed 
in Cushing’s syndrome is a consequence of the inherent 
hypercortisolaemia of the disease.48 As well as the effects 
on insulin sensitivity, cortisol is able to initiate adipogenesis 
in combination with insulin49 and also increases lipid 
deposition in mature adipocytes by up-regulating adipocyte 
lipoprotein lipase50 and inhibiting lipolysis.51 Cortisol is 
produced in adipocytes from inactive cortisone by the 
action of the enzyme 11β-hydroxysteroid dehydrogenase 
(11βHSD), the expression of which is increased in both 
visceral and subcutaneous adipocytes with increasing body 
fat mass.52,53 The cellular effects of cortisol are transduced 
via interaction with the glucocorticoid receptor, which has 
been shown to be expressed at higher levels in visceral 
than subcutaneous adipocytes.54 Thus, with increasing 
BMI, adipocyte production of cortisol will increase, leading 
to high local concentrations of the hormone. This will 
have greater effects in the visceral adipose depot due to 
higher glucocorticoid receptor expression at the intra-
abdominal site.54 The greater exposure or sensitivity of 
visceral, compared to subcutaneous, adipose tissue to 
cortisol has been suggested by other investigators as the 
reason for the visceral adipocentric effects of cortisol.53,55 
Thus, glucocorticoids may augment lipid accumulation 
in the visceral adipose tissue of obese subjects, allowing 
increased clearance of the triglycerides not taken up by the 
adipocytes within the subcutaneous fat depot.
Ethnic differences in body fat distribution
It is known that in subjects from the Indian subcontinent, 
type 2 diabetes, hypertension, ischaemic heart disease and 
the metabolic syndrome are all more common than in other 
population groups56 and that, at any given level of BMI or 
waist circumference, the level of cardiovascular disease 
risk factors is higher in Indian than in European subjects.57 
It has been demonstrated that the level of visceral fat is 
higher in Indian than in European individuals when matched 
for BMI or waist circumference,56,58 and this may partially 
explain the higher prevalence of cardiovascular disease in 
the former population. We might explain the higher level 
of visceral adiposity in Indian subjects by suggesting that, 
in this population, the subcutaneous fat depot has a lower 
capacity for triglyceride accumulation, and hence increased 
lipid accumulation in the visceral depot would occur at 
lower BMIs, as also hypothesised by Sniderman et al.10 
A possible explanation for this is that the subcutaneous 
adipocytes in Indian subjects are more insulin resistant 
compared to adipocytes in other ethnic groups, as has 
already been demonstrated,59 and this would lead to lower 
lipid storage in this fat depot. Also, serum levels of free 
fatty acids (FFAs) are higher60 and adiponectin lower61 in 
the Indian population. Both these molecules are products 
of adipocytes, with high levels of FFAs and low levels of 
adiponectin being associated with insulin resistance. 
However, given the multitude of recently discovered but 
yet to be fully characterised adipokines, it remains a point 
of conjecture whether ethnic differences in the production 
of one or more of these molecules by subcutaneous 
adipocytes might lead to higher levels of insulin resistance 
within the subcutaneous adipose depot of Indian subjects.
It is known that Indian neonates, although they have lower 
birth weights than those of other population groups, have 
proportionally higher levels of body fat, a phenotype that is 
preserved into adulthood.62 This suggests that the body fat 
pattern observed in Indian populations may be genetically 
determined. However, the genes involved have not yet been 
identified.
African women are known to have lower visceral63,64 
but higher subcutaneous64 fat mass than BMI-matched 
European women. This suggests that, in African women, 
the lipid storage capacity of the subcutaneous depot is 
greater than in European subjects, thus reducing lipid 
overflow into the visceral depot. The greater triglyceride 
storage capacity of the subcutaneous fat depot in African 
than European subjects may be related to the greater 
adipogenic rate observed in preadipocytes isolated from 
the former population group.65 Higher adipogenesis may 
reflect increased sensitivity to the adipogenic properties of 
insulin in subcutaneous preadipocytes of African subjects. 
However, one study has shown that mature adipocytes taken 
from the abdominal and femoral subcutaneous fat depots 
of African women are less sensitive to the anti-lipolytic 
action of insulin than those taken from European women.66 
These data were obtained using adipocytes isolated from 
obese subjects, and the study would have had greater 
relevance if the insulin sensitivity of adipocytes taken from 
lean individuals had also been examined. Therefore, more 
data are required to fully explain the differences in body 
fat distribution observed between European and African 
populations, although current observations suggest that the 
greater adipogenic capacity of subcutaneous preadipocytes 
in African women may play some role in producing ethnic 
differences in adipose depot mass.
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Conclusion
The control of body fat distribution must be viewed as an 
integration of different control systems, of which adipocyte 
insulin sensitivity is but one component. Other systems, 
particularly the endocrine axis, act directly on adipocytes 
but may also modulate adipocyte insulin functionality, 
which subsequently affects body fat distribution. The 
complex nature of the interactions that exist between these 
control mechanisms leads to difficulties in investigating 
and understanding the nature of the regulation of body 
fat distribution. It is for this reason that the use of high-
throughput molecular screening techniques may allow a 
clearer understanding of the subcellular mechanisms that 
are involved in the control of lipid deposition in the different 
adipose tissue depots. Already, GWA studies have revealed 
interesting new data with regard to the genetic input into 
body fat distribution, and the use of proteomic and gene 
expression profiling technology will undoubtedly add to our 
limited knowledge of how body fat depot size and function 
are controlled. A fuller understanding of these pathways will 
lead to increased knowledge on the aetiology of obesity-
related metabolic disorders and will hopefully progress to 
new interventions for these diseases.    
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